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The need for a new antibiotic pipeline to confront threat imposed by resistant pathogens has become a
major global concern for human health. To confront the challenge there is a need for discovery and devel-
opment of new class of antibiotics. Nature which is considered treasure trove, there is re-emerged inter-
est in exploring untapped microbial to yield novel molecules, due to their wide array of negative effects
associated with synthetic drugs. Natural product researchers have developed many new techniques over
the past few years for developing diverse compounds of biopotential. Taking edge in the advancement of
genomics, genetic engineering, in silico drug design, surface modification, scaffolds, pharmacophores and
target-based approach is necessary. These techniques have been economically sustainable and also pro-
ven efficient in natural product discovery. This review will focus on recent advances in diverse discipline
approach from integrated Bioinformatics predictions, genetic engineering and medicinal chemistry for
the synthesis of natural products vital for the discovery of novel antibiotics having potential application.
 2018 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research & Technology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Microbial natural products (MNPs) have been a prominent
source for drug discovery since the discovery of the penicillin
by Alexander Fleming. MNPs has been critical importance in ther-
apeutically viable drugs against infectious diseases, antioxidants,
cancer, diabetes, etc. [1] During the age of antibiotic discovery
1940–1970 has been accounted for major antibiotics known
today as a result of vast screening efforts by natural product
researchers. FDA assessment of natural products reveals that
nearly one-quarter of these has been derived from microbial
sources [1,2]. The long-established approach of ‘herbal remedy’
has been substituted with precise compounds emerging from
the gene and molecular altered microbial products. Hence, micro-
bial natural products have replaced plant-derived compounds as a
source of therapeutic agents and has been a potential source for
the discovery of novel therapeutics in the past decades. In recent
years, there has been declination of natural products but an
increase in their synthetic derivatives. This has greatly impacted
therapeutic pipeline from the exploration of novel natural prod-
ucts being abandoned in the last decade by pharmaceutical indus-
tries. The perception of all the major classes of antibiotics had
been found to be the main reason for the abandonment. Synthetic
drugs have been preferred as screening methods for natural prod-
ucts, resulted in redundant isolates than novel compounds, also
due to large-scale amount and time required for discovery [3].
Nowadays, the funding opportunities have been provided through
academia, charities and governmental institutions for the quest.
Due to the emergence of antimicrobial resistance (AMR), the
antibiotic pipeline for combating serious life-threatening infec-
tions is almost empty against drug-resistant pathogens [1,2].
But, the diversity of chemical skeletons provided by MNPs has
been a ray of hope. To tackle the unmet clinical challenge posed
by multidrug resistance and also to cure ailments there is a need
to readdress the issue with a new class of antibiotics through
innovative approaches with completely different new framework
using a directed synthesis of MNPs [2]. Earlier studies state natu-
ral products, as a result of evolutionary modification by mutation
or through variation leading to change in the biosynthetic path-
ways for emergence bioactive molecules with the potency and
selectivity to bind to biological targets [3,4]. This has attracted
natural product researchers to explore the enzymology and
biosynthesis for modulation possibilities for new molecular enti-
ties. There have been several new techniques developed for the
natural product discovery in the recent years, initiating a ‘new
era in natural therapeutic discovery’.
This review is an effort to examine the current scenario, new
approaches for exploration of natural therapeutics and also high-
lights recent reports of novel natural products derived from recent
drug discovery technologies.2. Microbial natural products as therapeutics
Threat imposed by drug-resistant pathogens has been a global
concern. The inefficacies of available antibiotic pipeline in combat-
ing existing multidrug-resistant pathogens has been a critical issue
in recent years. This has been attributed due to overexploitation
antibiotics resulting in resistance to these pathogens. MNPs could
be a prominent strategy for meeting the present preclinical requi-
site exerted by drug-resistant pathogens. MNPs have unusual
chemical skeletons and diversification which could target varied
regions leading to the potential for drug discovery. The regained
interest of natural products with the amalgamation of cutting-
edge developments in drug discovery has gained utmost impor-tance for a targeted approach. MNPs have offered an efficient
source of new drug leads, however, it is attributed to evolutionary
advantage by selective mutation for the organism. In this regard
concoction of untapped sources with recent advances in drug dis-
covery techniques would enable to provide a new class of antibi-
otics. MNP analogue libraries could provide a base for medicinal
chemistry for pharmaceutical profiling for enhancing the desired
phenotype as well as providing insights on target and pathways
[5,6].3. Antibiotic resistance
Antibiotics had been effective against prevalence and preven-
tion of infections in the yesteryears. But, recently there has been
a complication of resistance adopted by most of the pathogens in
the pipeline of available antibiotics. The resistance has been
linked to overexploitation of antibiotics leading to molecular,
gene, cellular and community level resistance. Antibiotics have
high affinity to the targets if there is a single point of mutation
could trigger the surface resulting in resistance and proliferation
as well transfer of resistance gene by transformation. Enzyme
catalysed inactivation of antibiotics by hydrolysis has been crucial
reason for failure b lactam antibiotics preventing cell penetration,
alteration of targets and resisting the action of antibiotics [7]. For-
mation of biofilms has been one of the major reasons for antibi-
otic failure. Microbes conglomerate to form biofilms leading to
irreversible attachment to the biotic/abiotic surface. Biofilms aid
consortia of microbes against oxidative stress, increase in specific
efflux pumps and also protection by providing an outer layer of
extracellular polysaccharide layer. In addition, the transfer of
antibiotic resistance genes by horizontal gene transfer is found
to be in increased levels [8,9]. Hence, the concentration of antibi-
otic to inhibit these planktonic cells is much higher when com-
pared to sessile cells.4. Regulation of antibiotic biosynthesis
Antibiotics are secondary metabolites without a functionalised
role in cell growth or reproduction. Antibiotics inherit specialised
functions, which trigger intra/intracellular signalling (such as Car-
bon Catabolite Regulation, Nitrogen Metabolite Regulation, Phos-
phate Regulation), either for communication, nutrition and
defence. The major diversity of antibiotics is attributed to combi-
nation synthesis of polyketides (PKS), non-ribosomal peptides
(NRPS) pathways [10,11].5. Conventional discovery and development of antibiotics
Drug discovery involves identification of compounds with
potential for blocking a single gene, gene product or molecular
mechanism determined by genetic analysis or biological observa-
tions associated with the disorder [12]. Drug discovery involves
multistep process Fig. 1. Target identification, assay development,
screening, Hits and lead identification, lead optimization, drug
development and clinical trial [13].
Identification of target is a crucial preliminary step in drug dis-
covery. The target could be an enzyme or protein which needs to
be either blocked or activated to induce response for the cure of
abnormality. Assay development involves a quest for bioactive
compounds e.g., bioautography, paper disk method inhibiting the
target to restore homeostasis. Screening enables high-throughput
data for analysing a multitude of compounds. Hits and leads stage,
a variety of parameters are examined such as the specificity, toxi-
city, and molecular structure of the bioactive molecule. Lead
Fig. 1. Multi step process of conventional drug discovery.
N. Chandra Mohana et al. / Journal of Genetic Engineering and Biotechnology 16 (2018) 1–8 3optimization is employed to ameliorate specificity, reduce toxicity,
and also to enable a wide antibiotic spectrum of lead compound
[14]. Once the criteria are achieved according to standards, drug
development and clinical trials are followed. The drug is tested
for safety and efficacy, in animal models preliminarily, followed
in three stages on humans in clinical settings.6. Omics based approach for biodiscovery of microbial natural
products
6.1. Potential sources of microbial antibiotics for drug discovery
Unique niche in extreme climatic conditions, unusual land-
scapes and geographical location leading to the multiplex of adap-
tations (physiological and behavioural) could result in unusual
biology for inhabiting species. These unique reservoirs are a poten-
tial source to isolate broad assemblage of microbes having phar-
maceutical value. Advancement in metagenomics has resulted in
the knowledge base of diverse and complex microbial communi-
ties surviving in lakes, rivers, sediments and marine environments,
also in extreme conditions like ice cores, hydrothermal vents, sub-
seafloor sites and caves. These bio-diverse populations could serve
as an antibiotic mining source, having diverged and variable chem-
ical structures of pharmaceutical interest [15,16] (Fig. 2).Fig. 2. Omics based approach for biodiscovery of microbial natural products.6.2. Genome mining
In the past decade, genome mining as an alternate strategy
which has been considered against traditional screening for drug
discovery. The genome mining approach aid in identifying and pre-
diction analysis of biosynthetic gene clusters from genes to mole-
cules. With a large library of information of DNA existing with the
computational approach, there is the probability of wide array of
novel molecules encoded in genome providing a new class of
antibiotics. Genome mining has proved to be fast, the user-
friendly and reliable technique also cost effective. Mining of gen-
ome has been potential for previously unfeasible antibiotics. The
mining approach would enable target directed discovery by pre-
dicting the chemical structure and class using bioinformatics in
amalgamation with bioassay-guided isolation, along with silent
gene activation and heterologous expression techniques for novel
bioactive metabolites [17,18]. For instance, polyketides (PKs) and
non-ribosomal peptides (NRPs) represent abundances of molecules
with biological diversity such as daptomycin, erythromycin, and
many others. NRPs and PKs of microbial origin represents a signif-
icant proportion of natural bioactive products. The accumulated
knowledge of the NRPSs or PKSs constituting biosynthetic path-
ways or another type of NPs gene clusters helps to predict and iso-
late new gene clusters, engineering or production of NPs in
heterologous hosts. There has been a significant development in
a number of algorithms developed based on probabilistic approach,
evolutionary distances in the genome to understand the pathways
for biosynthesis of natural products. Most of the algorithms pre-
sently employed are based on domains and Pfam regions in well-
known secondary metabolite pathways such polyketide synthases
(PKS) and non-ribosomal peptide synthatases (NRPS).
Cluster Assignment by Islands of Sites (CASSIS) was developed
by Wolf et al. CASSIS scans the genome (FASTA format) for key
enzymes prerequisite for secondary metabolite production such
as polyketide synthases (PKS), non-ribosomal peptide synthetases
(NRPS) and dimethylallyltryptophan synthases [19]. Another pro-
gram antiSMASH 3.0 was developed by Weber et al. an updated
version of the previous server-based program. The program uses
the probabilistic approach and allows the user to input using
multi-FASTA, GenBank and EMBL formats. The embedded modified
Cluster Blast and ClusterFinder with better sensitivity and speci-
ficity to identify biosynthetic gene clusters has potential for dis-
covering novel drugs [20]. A new PKS-NRPS hybrid product,
Fig. 3. Epigenetic activation strategies.
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SMASH from myxobacterium Haliangium ochraceum. The biosyn-
thetic gene cluster constituted one NRPS module with four PKS
modules having 21.7 kbp. The putative gene cluster harboured in
myxobacterium could lead to the isolation of additional com-
pounds with biological potential [21]. Salinilactam, a polyene
macrolactam was discovered along with 17 novel biosynthetic
gene clusters coding for polyene derivatives from a marine actino-
mycete Salinispora tropica [22]. Genome mining and genetic
manipulations strategies were employed on marine actinomycete
Streptomyces olivaceus yielded two new naphthoquinone macro-
lides olimycins A and B [23]. A 92 kb cryptic biosynthetic gene
comprising hybrid polyketide and nonribosomal peptide marine
Streptomyces pactum, was activated by genetic modification
resulted in a novel sulfonate containing analogue totopotensamide
C [24]. Sweeney et al. reported the genome mining of Streptomyces
nodosus, the organism constituted several biosynthetic gene clus-
ters for polyketides, peptides, siderophores and terpenes synthesis.
These compounds were found to be expressed in low quantities or
silent in comparison with amphotericin expression [25]. The nota-
ble anti-infectives through mining approach include clarepoxcins
and landepoxcin [26], cypemycin, [27] haloduracin [28], Lactocillin
[29], microcyclamide [30], teixobactin [31] reistomycin [32],
microviridin [33] and microbisporicin [34] to mention in few.
Besides the above programs there are 2metDB, BAGEL, CLUSEAN,
ClusterFinder, eSNaPD, EvoMining, FunGeneClusterS, MIDDAS-M
and SMURF [35–43].
Beside these antibiotics, other novel bioactive natural products
include EstDZ2 bacterial esterolytic enzyme possessing moderate
thermostability which exhibited stability to withstand high con-
centrations of organic solvents [44], BP-M-CPF4 (PhaC) a polyhy-
droxyalkanoate (PHA) synthase possessing very wide substrate
specificity [45], EM3L4 lipase retaining salt-resistance property
[46], genome mining studies by Roopa et al. for taxol from endo-
phytes of Salacia oblonga revealed a total of 8 mycoendophytes,
seven coded for DBAT (deacetylbaccatin III-10-O-acetyl trans-
ferase) and one for BPAT (C-13 phenylpropanoid side chain-CoA
acyltransferase) proving the mining strategies, as a potential tool
for new taxol derivatives possessing anticancer activity [47].
Streptomyces coelicolor genome mining revealed locus SCO 7131
of estA gene suggested that it might differ in substrate specificity
with respect tomembers of the hormone-sensitive lipase (HSL) fam-
ily of lipases and esterases. The estA gene was expressed using His-
tagged protein in Escherichia coli, enzyme purified was found to be
an esterase, which hydrolyzed the acetate ester of p-nitrophenol,
but possessed mild activity on esters with longer side chains and
exhibited optimal activity against caproate (C6) esters.Modification
using site-directed mutagenesis led to an increased activity against
butyrate and caproate esters but affected by reducing the ther-
mostability of the enzyme. Using the genome mining data, the
changes in the amino acid in conserved regions to indicate active
sites could be employed for characterization of novel enzymes
[48]. Genome mining of Streptomyces coelicolor revealed beyond
50 presumptive genes for putative lipolytic enzymes. EstC, purified
recombinant enzyme from the gene cluster exhibited cold-active
esterase activity along with the production of valuable esters. The
enzyme possessed alcohol and organic solvent tolerance, which
could be employed for organic synthesis of short-chain esters such
as flavours [49]. Genomemining is a powerful toolbox for novel nat-
ural products biosynthesis and also to decipher regulation, distribu-
tion as well as elucidating biosynthesis pathways.
6.3. Epigenetic activation
The metagenomics facilitated the next generation sequencing
technology has provided insights towards the cryptic gene clusters.Various strategies have been put in effort past decade towards acti-
vating these silent gene clusters for new drugs. Many techniques
have been put forward by natural product researchers in the past
decade such as activation by gene elicitors, using heterologous
hosts, regulating factors and co-cultivation for expression of gene
clusters [50,51].
Four gene clusters involved in the synthesis of sterigmatocystin,
penicillin, terrequinone and orsellinic acid by H4 acetylation tar-
gets was reported by Soukup et al. The histone acetyltransferase
had a crucial role in the synthesis of secondary metabolites and
epigenetic regulation in Saccharomyces cerevisiae [52]. Du et al.
reported new chlorinated polyketide, daldinone E a potent antiba-
caterial from Daldinia sp. using epigenetic modifier suberoylanilide
hydroxamic acid (SAHA) [53]. Expression and production of
polyketides have been difficult due to imitating factors such as
Posttranslational Modification, Substrate Availability, Intracellular
Factors, Transmembrane Transporters Post-PKS Polyketide Modifi-
cation, Self-Resistance exerted by parent strain. The following can-
didates have been utilised in recent year as heterologous hosts
Streptomyces coelicolor, Streptomyces glaucescens, Saccharopolyspora
erythraea, Saccharomyces cerevisiae [54], Aspergillus oryzae and
Aspergillus nidulans [55] which could serve robust, economically
feasible and efficient system for production of compounds with
pharmacological interest. Kumpfmüller et al. recently reported 6-
deoxyerythronolide B (6dEB) by Bacillus subtilis. To enhance the
production gene knockout surfactin (26 kb), bacillaene (76 kb),
and plipastatin (38 kb) resulting in deletion of the prpBD operon
showed a significant increase of the 6dEB yield. The study indi-
cated B. subtilis could serve as a candidate for heterologous expres-
sion for the synthesis of complex polyketide [56] (Fig. 3).6.4. Combinatorial biosynthesis
Combinatorial biosynthesis can be generally referred as ‘‘in-
duced evolution” for designer antibiotics through genetics and/or
medicinal chemistry. The engineering of novel chemical entities
by combinatorial approach utilises the key enzymes involved in
secondary metabolite of antibiotic synthesis pathways such as
polyketide synthase (PKS), nonribosomal peptide synthase (NRPS),
thioesterase (TE), acyl transferase (AT), 6-deoxyerythronolide B
synthase (DEBS), dehydratase (DH), enoyl reductase (ER), ketore-
ductase (KR) and ketosynthase (KS). The combinatorial synthesis
has been proven successful between antibiotic-producing organ-
isms for producing hybrid gene products. The feasibility of tech-
nique has been efficient among organisms constituting PKS gene
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and multifunctional roles [57–59]. PKS and NRPS assemblies con-
stitute large enzymes composed of polypeptides ranging from
100 kDa to MDa. The antibiotic synthesis involves gene to enzyme
creating chemical triggers in assembly-line fashion to synthesize
the final product. To achieve effective biosynthesis natural product
researchers must balance the antibiotic synthesis pathway with
host cell growth which could possibly by achieved genetic engi-
neering in certain scenarios.
Nine xantholipin analogues were obtained using PKS tailoring
modification from Streptomyces flavogriseus. Biosynthetic gene
cluster constituted 52 kb encoding xantholipin gene with type II
polyketide synthases and regulators. In-frame mutagenesis of five
enzymes resulted in new derivatives which were catalysed by FAD
binding monooxygenase XanO4, followed by bridge formation by
P450 monooxygenase XanO2 and hydroxylation of the carbon
skeleton by the FAD-binding monooxygenase XanO5. The poly-
cyclic polyketide derivatives can be potent antibiotic as well as
antitumour [60]. Post PKS one step tailoring in putative cyto-
chrome P450 monooxygenases, MakC2 and MakC3 resulted in a
new spirotetronate-class antibiotic 29- Deoxymaklamicin from
Maklamicin biosynthesis pathway in Micromonospora sp. 29-
Deoxymaklamicin was found to be inhibitory against gram-
positive bacteria [61].
6.5. Genome shuffling
Conventionally the utilising random mutation and screening
strategies had been used, although having some advantages it’s
economically not feasible, labour and time intensive. With
advancement in the ‘omics’ era, genome shuffling has been an
alternate strategy which could even be employed in complex phe-
notypes which were difficult earlier. Genome shuffling with aid of
advanced genetic tools has been able to assist in targeted genetic
manipulation for a phenotype. The technique has been reliable
for offering both strain improvement, also more providing insights
into cellular information of the desired phenotype. Many mole-
cules have been developed using directed evolution with DNA
shuffling which has been a convenient strategy for whole cell
and metabolic engineering. A concoction of high throughput anal-
ysis with in silicomodelling/simulations has enabled to understand
the global context of the metabolic system. Whole genome engi-
neering could be considered as an inspiration from natural evolu-
tion which is a selection of desired phenotypic traits. With
advancements in experimental and computational techniques gen-
ome shuffling has caught global consideration. The DNA shuffling
allows accelerated directed evolution and pathway engineering,
which is crucial for strain improvement of industrially important
microorganisms [62,63].
Increased production of avilamycin from Streptomyces viri-
dochromogenes, from protoplast fusion, resulted in 36.8-fold in
the recombinant. Mutation in ribosome protein S12 was consid-Fig. 4. Genome shufflinered the factor responsible for enhanced production as the well
morphological difference in conidiospore, and hyphae pellets from
the parent. The compound inhibits Staphylococcus pneumoniae,
Streptococcus pyogenes, Enterococcus faecalis, Enterococcus
faecium, methicillin-resistant Staphylococcus aureus (MRSA), and
methicillin-resistant Staphylococcus epidermis (MRSE). The combi-
nation of genome shuffling and ribosome engineering was success-
ful in improving the phenotype for yield production of avilomycin
[64] (Fig. 4).
6.6. Metabolomics
Metabolomics provides high throughput analysis of metabolites
and simultaneous comparison platform of biological samples pro-
viding insights on crucial roles in cellular processes, intra-organ
and inter-organ communications. The analysis of the metabolome
is especially arduous because of the varied chemical nature of
metabolites. Metabolomics is an expeditious turning into one in
all the platform sciences of the ‘omics’. The technique is an exten-
sion of identification that is predicated on the drug target identifi-
cation and it’s biological transformation sanctions, the drug
replication data for a clinical disorder. This review of the utilisation
of metabolomics in integrated applications wherever metabolo-
mics data has been amalgamated with different ‘omic’ cognizance
sets to transmute more immensely colossal understanding of a bio-
logical system. The potential of metabolomics for natural product
drug revelation and practical analysis, primarily as incorporated
into broader ‘omic’ erudition sets is enormous. Recent advances
in metabolomics technologies have been extensively applied in
biomedical applications. Especially, metabolomics is progressively
being employed in disease diagnose, determining novel drug tar-
gets, custom designed drugs and supervise therapeutic conse-
quence. The expeditiously developing field of metabolomics
consolidates methodologies to apperceive and quantify cell
metabolites utilising multi-variation strategies for data mining
and information processing. Concurrently, substantial notional
theorizations were made to investigative ways to decipher distinc-
tive cell items, for example, those from quality articulation (tran-
scripts), proteins, and metabolites. These alleged omics
approaches, including genomics, transcriptomics, proteomics, and
metabolomics, are viewed as vital contrivances to be connected
and used to comprehend for drug discovery. A scope of analytical
advances has been made to investigate metabolites in biological
samples. It has been suggested that metabolomics greatest poten-
tial lies in disease marker revelation and detection. These metabo-
lites are not only biomarkers for the disease but additionally
accommodate as ‘biomarkers of efficacy’. This designates they
sanction the utility of incipient drug which has to be rapidly
assessed in cell-predicated or enzymatic assays. Furthermore,
some metabolites may accommodate as potential targets for incip-
ient drug therapies or as potential drugs, in and of themselves.
Many genetic disorders arise from multiple gene defects and beingg for novel MNPs.
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root causes which are critical in finding out the drug targets, felic-
itous drugs or cumulations of dietary supplements to treat them
[65–67]. Metabolomics has made an impact on drug revelation
and development processes dramatically by quantifying accurately
the spectrum of biochemical changes and mapping these vicissi-
tudes to metabolic pathways. This technology provides data that
is less intricate, precise, germane and quantitative than genomics,
transcriptomics or proteomics. With this methodology, it is now
possible to develop a construal of disease states and incipient
treatment modalities much more expeditious and more accurately
than before. Metabolomics has broad applications across the drug
revelation and development processes. Metabolomics is a puissant
and new scientific approach for the revelation and development of
drugs and the early diagnosis of disease onset.
The integration of ‘omics’ knowledge has potential in natural
product drug discovery [68]. One of the often-perceived hurdles
committed natural product drug discovery is that the chance of
redundancy. There are numerous ‘dereplication’ procedures, which
have established to deal with this drawback, significantly
employed by researchers focusing on microbial drug leads. NMR
and MS-based platform give structural information of metabolites
in an early stage, the comparison of structural information pro-
cured by NMR and high-resolution mass spectrometry with litera-
ture. If structures are reported, discriminators can be identified
without the need for laborious isolation process. Thus, metabolo-
mics serves as an approach for dereplication.
New prenylated Isatin antibiotic Streptomyces Species MBT28
was reported using NMR-based metabolomics. NMR-guided isola-
tion was achieved by tracking the target proton signal which
resulted in the characterization of a 7-prenylisatin antibiotic effec-
tive against Bacillus subtilis. NMR-based metabolomics with pro-
teomic approach facilitated identification of gene cluster which
deciphered an enzyme indole prenyltransferase that catalyzed
the conversion of tryptophan into 7-prenylisatin [69]. Wu et al.
reported novel C-glycosylpyranonaphthoquinones in Streptomyces
sp. MBT76 utilising combined approach of NMR based metabolo-
mics and mining strategy. The qin gene cluster of type II PKS path-
way was activated leading to 8-C-glycosylation, 5,14-epoxidation,
and 13-hydroxylation also fusing deoxy aminosugar to the pyra-
nonaphthoquinone. The new C-glycosylpyranonaphthoquinones
were effective against Gram-positive bacteria, which led insight
to pyranonaphthoquinone antibiotics [70]. Metabolomic analysis
using high-resolution LC-MS and NMR for dereplication purposes
was employed in the study of 64 actinomycetes was isolated from
12 different marine sponge species. The LC-MS/NMR based detec-
tion aided in prioritizing two isolates belonging to the genera
Streptomyces (SBT348) andMicromonospora (SBT687) which exhib-
ited distinct chemistry profiles. The isolates possessed potent anti-
trypanosomal activities. The chemically unique strains were pro-
filed rapidly with utilisation hyphenation techniques of metabolo-
mics [71]. Chemical communication in co-culture of Cladosporium
sp. WUH1 and Bacillus subtilis CMCC (B) 63,501 resulted in the pro-
duction of previously reported diphenyl ethers with polyhydroxy
sidechains including a novel antibiotic. The metabolomic approach
integrating LC-MS analysis, along with statistical tools and molec-
ular networking revealed diphenyl ethers might be a defensive
response against growth inhibition resulting from surfactins by B.
subtilis [72]. A series of lipidic spirohemiaminals possessing broad
antimicrobial activity were reported by surveying unique molecu-
lar signatures identified in the mass spectrometry data obtained by
co-culture of Streptomyces nigrescens HEK616 and Tsukamurella
pulmonis TPB0596 [73]. NMR-based metabolomics combined with
multivariate data analysis was employed in the determination of
secondary metabolites produced by co-culture of revealed A. niger
and S. coelicolor. The biotransformation studies revealed synthesisof novel compounds (E)-2-(3-hydroxyprop-1-en-1-yl)-phenol and
(2E, 4E)-3-(2-carboxy-1-hydroxyethyl)-2, 4-hexadienedioxic acid,
respectively [74]. The comparison of the metabolome profile of
the co-culture with that of the individual microorganisms would
enlighten differentiation of induced metabolites present in co-
culture but absent in monocultures, also these de novo-
engineered molecules have high chances of being novel com-
pounds or new derivatives with biological activity.
Metabolomics approach for natural product discovery greatly
depends on natural product libraries which enable rapid character-
ization of known compounds. Spectroscopic data libraries such as
TCM Database@Taiwan, traditional Chinese medicine integrative
database (TCMID), Chinese ethnic minority traditional drug data-
base (CEMTDD), SuperToxic, NPACT, 3DMET DNP (Dictionary of
Natural Products), Dictionary of Marine Natural Products, ACD/
Labs NMR, ACD/Spectrus, UCSD Natural Products Database Napra-
lert, NuBBE and SuperNatural have been developed over the recent
years [75,76].
Metabolomics, the study of the whole repertoire of tiny mole-
cules in cells, tissues, organs, and biological fluids, which repre-
sents a significant and speedily evolving part of the new systems
biology. Relative to different omics fields, metabolomics remains
a comparatively young discipline. There are challenges in terms
of technology, experimental design, information analysis, and
information integration that may influence the sphere of metabo-
lomics and its application to systems biology. However, many
advances in metabolomics technologies have been developed.
Instrumentation has been quicker, more sensitive with reliable
and automated reducing of any error in constituent measurements,
also applied statistical analyses for data validation. Given the
potential of this technology in this field, there is a rise in the num-
ber of publications in the recent years. Metabolomics has real
potential to facilitate the study of systems biology for predicated
drug revelation by assessing drug response and its adverse reaction
along with variation involved for natural product biodiscovery.7. Conclusion
The regained interest in evaluating the efficacy of natural prod-
ucts from microbes as a source of new drugs is very crucial for
antibiotic drug discovery. The conventional approach of antibiotic
discovery should be re-evaluated with high-throughput screening,
metagenomics and metabolomics for the pursuit of novel com-
pounds. The amalgam of metagenomics with genomics, genetic
engineering and medicinal chemistry would provide exciting novel
antibiotic leads that could serve the issue of antibiotic resistance.
The quest for novel bioactive natural products by the advancement
of leading technologies has gained spotlight. Regardless of, amelio-
ration in culturing techniques still render drawback of microbe
uncultivable. With the advent of metagenomics have aided in iso-
lation, identification and sequencing of these microbes. The boost
in the knowledge base of microbe diversity in extreme environ-
ments with help of metagenomics has opened a new direction in
the identification of novel isolates. Combination of metagenomics
with recent developments of understanding in genome mining,
genetic engineering, in silico design, metabolomics and medicinal
chemistry could aid in the development of target-specific bioactive
molecules for multifaceted necessities.Acknowledgements
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